Meronia IV 500 mg

Form: IV injection
Dosage: 500mg
Packaging: Powder for 20 ml solution for injection or infusion

Active substance :  meropenem

Form : Powder for solution for injection or infusion

Dosage :  500 mg per vial Meronia 500 IV  / 1000 mg per vial Meronia 1000 IV

Packaging :

Box with 1  20 ml vial for Meronia 500 IV

Box with 1  20 ml vial for Meronia 1000 IV

Target : Adults and children from 3 months and older

Clinical experience indicates that the product can also be given to younger children

Meronia IV is indicated for the treatment of the following infections in adults and children aged 3 months and older.

  • Severe pneumonia, including hospital and ventilator‐associated pneumonia.
  • Broncho‐pulmonary infections in cystic fibrosis
  • Complicated urinary tract infections
  • Complicated intra‐abdominal infections
  • Intra‐ and post‐partum infections
  • Complicated skin and soft tissue infections
  • Acute bacterial meningitis
  • in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
  • Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.

Unit doses in function of the infection :  500 mg to 1000 mg  to be given each 8 hours

Children below 11 y of age (<50kg)  : 10 to 20 mg/kg , mg  to be given each 8 hours

A dose of up to 2 g three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections due to less susceptible bacterial species or very severe infections.

Method of administration :

– Meronia is usually administered as an intravenous infusion over approximately 15 to 30 minutes.

– It is also possible to administer doses of Meronia up to 20 mg/kg as an intravenous bolus over approximately 5 minutes.

There is evidence from clinical experience as well as recent scientific literature of prolonged infusion for up to 3 hours with very good efficacy and less risk of adverse effects.

A solution for bolus injection is prepared by diluting the product in water for injection to a final concentration of 50 mg/ml.

A solution for infusion is prepared by diluting the product in either 0.9% sodium chloride solution for infusion or 5% dextrose solution for infusion to give a final concentration of 1-20 mg/ml.

The chemical and physical stability of use has been demonstrated for 3 hours up to 25°C or 12 hours under refrigerated conditions (2-8°C).

From a microbiological point of view, unless the risk of bacterial contamination during opening, reconstitution and dilution is eliminated, the product must be used immediately.

If not used immediately, storage times and conditions are the responsibility of the user.

Prescription drugs. Please contact your doctor.

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo ( In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma